Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Eur J Med Chem. 2022 Jan 5;227:113934. doi: 10.1016/j.ejmech.2021.113934. Epub 2021 Oct 20.
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis methods and biological features of the most potent dual NO-HDAC inhibitor in each category with the intention of assisting in the synthesis and optimization of new drug-like compounds for diverse diseases. Based on studies done so far, NO-HDAC dual inhibitors have displayed satisfactory results against wound healing (3), heart hypertrophy (3), inflammatory, cardiovascular, neuromuscular illnesses (11a-11e) and cancer (6a-6o, 9a-9d, 10a-10d, 16 and 17). NO-HDAC dual inhibitors can have high therapeutic potential for various diseases due to their new properties, NO properties, HDAC inhibitor properties and also due to the effects of NO on HDAC enzymes.
HDAC 抑制剂和 NO 供体在多种疾病中均表现出广泛的治疗潜力。Borretto 等人于 2013 年首次提出了 NO-HDAC 双重抑制剂这一极具吸引力的新课题。在这里，我们收集了所有合成的 NO-HDAC 双重抑制剂的一般结构、先导化合物、合成方法和每一类中最有效的双重 NO-HDAC 抑制剂的生物学特性，旨在为治疗各种疾病的新型类似药物的合成和优化提供帮助。根据迄今为止的研究，NO-HDAC 双重抑制剂在伤口愈合（3）、心脏肥大（3）、炎症、心血管、神经肌肉疾病（11a-11e）和癌症（6a-6o、9a-9d、10a-10d、16 和 17）方面显示出了令人满意的效果。由于其新特性、NO 特性、HDAC 抑制剂特性以及 NO 对 HDAC 酶的影响，NO-HDAC 双重抑制剂可能对多种疾病具有很高的治疗潜力。
